Xtant Medical Holdings (Xtant Medical Holdings) Gross Margin % : 60.97% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Xtant Medical Holdings's Gross Profit for the three months ended in Dec. 2023 was $17.14 Mil. Xtant Medical Holdings's Revenue for the three months ended in Dec. 2023 was $28.11 Mil. Therefore, Xtant Medical Holdings's Gross Margin % for the quarter that ended in Dec. 2023 was 60.97%.

Warning Sign:

Xtant Medical Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -1.6%.

The historical rank and industry rank for Xtant Medical Holdings's Gross Margin % or its related term are showing as below:

XTNT' s Gross Margin % Range Over the Past 10 Years
Min: 55.44 Med: 61.93 Max: 69.21
Current: 60.75

During the past 13 years, the highest Gross Margin % of Xtant Medical Holdings was 69.21%. The lowest was 55.44%. And the median was 61.93%.

XTNT's Gross Margin % is ranked better than
60.8% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.295 vs XTNT: 60.75

Xtant Medical Holdings had a gross margin of 60.97% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Xtant Medical Holdings was -1.60% per year.

Xtant Medical Holdings Gross Margin % Historical Data

The historical data trend for Xtant Medical Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings Gross Margin % Chart

Xtant Medical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

65.73

64.48

58.79

55.44

60.75

Xtant Medical Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															54.39	58.72	61.58	61.29	60.97

Competitive Comparison of Xtant Medical Holdings's Gross Margin %

For the Medical Devices subindustry, Xtant Medical Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xtant Medical Holdings's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Gross Margin % falls into.

Xtant Medical Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Xtant Medical Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	55.5	/	91.303
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(91.303 - 35.836)	/	91.303
	=	60.75 %

Xtant Medical Holdings's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	17.1	/	28.108
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(28.108 - 10.971)	/	28.108
	=	60.97 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Xtant Medical Holdings (AMEX:XTNT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Xtant Medical Holdings had a gross margin of 60.97% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Xtant Medical Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

XMS:Germany

Address

664 Cruiser Lane, Belgrade, MT, USA, 59714

Website

http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Executives

Kevin D Brandt	officer: VP & Chief Commercial Officer	11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller	director	664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson	director	664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils	officer: Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger	officer: Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne	officer: President and CEO	664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis	director	1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc	director, 10 percent owner	601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen	officer: VP, Finance and Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin	officer: VP & Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen	officer: SVP Fiance & Admin. & CFO	664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750